Summit Therapeutics Ownership | Who Owns Summit Therapeutics?

Overview ForecastFinancials Chart Transcripts

Summit Therapeutics Ownership Summary

Summit Therapeutics is owned by 17.64% institutional investors, 80.89% insiders, and 1.47% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 4.23% of SMMT shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 0.92% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Summit Therapeutics	17.64%	80.89%	1.47%
Sector	Healthcare Stocks	244.37%	12.11%	-156.48%
Industry	Biotech Stocks	379.01%	11.75%	-290.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	32.79M	4.23%	$477.70M
Vanguard group	11.18M	1.50%	$195.49M
Fmr	10.04M	1.30%	$146.34M
State street	9.54M	1.23%	$138.95M
Blackrock funding, inc. /de	9.53M	1.23%	$138.84M
Blackrock	7.90M	1.13%	$61.61M
Vanguard capital management	5.73M	0.74%	$83.55M
Ubs group	5.23M	0.67%	$76.26M
Goldman sachs group	4.51M	0.58%	$65.76M
Price t rowe associates inc /md/	3.89M	0.50%	$56.73M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Apeiron capital	961.87K	9.00%	$14.01M
Cutter capital management, lp	400.00K	3.36%	$7.72M
Baker bros. advisors lp	32.79M	2.39%	$477.70M
Sectoral asset management	220.18K	2.24%	$3.21M
Octagon capital advisors lp	1.25M	1.64%	$18.21M
Kynam capital management, lp	1.20M	0.97%	$17.48M
Logos global management lp	1.35M	0.85%	$19.67M
Rock springs capital management lp	715.00K	0.51%	$10.42M
Hohimer wealth management	339.10K	0.49%	$4.94M
Tang capital management	550.00K	0.44%	$11.36M

Top Buyers

Holder	Shares	% Assets	Change
Goldman sachs group	4.51M	0.01%	4.20M
Point72 asset management	3.70M	0.06%	2.91M
State street	9.54M	0.00%	2.51M
Millennium management	2.35M	0.01%	2.22M
Adage capital partners gp	1.99M	0.04%	1.99M

Top Sellers

Holder	Shares	% Assets	Change
Price t rowe associates inc /md/	3.89M	0.01%	-4.38M
Baker bros. advisors lp	32.79M	2.39%	-3.60M
Blackrock	7.90M	0.00%	-1.92M
Darwin global management	-	-	-1.08M
D. e. shaw	1.24M	0.01%	-998.67K

New Positions

Holder	Shares	% Assets	Change	Value
Adage capital partners gp	1.99M	0.04%	1.99M	$28.99M
Norges bank	1.38M	0.00%	1.38M	$20.14M
Logos global management lp	1.35M	0.85%	1.35M	$19.67M
Octagon capital advisors lp	1.25M	1.64%	1.25M	$18.21M
Kynam capital management, lp	1.20M	0.97%	1.20M	$17.48M

Sold Out

Holder	Change
Root financial partners	-1.00
Bay harbor wealth management	-2.00
Clearstead advisors	-2.00
Cassaday & co wealth management	-2.00
Hfm investment advisors	-2.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	266	10.83%	136,779,131	15.02%	17	7.50%	157	12.95%	57	5.56%
Mar 31, 2026	104	-53.15%	23,850,252	-79.75%	3	1.27%	60	-46.43%	21	-69.12%
Dec 31, 2025	64	-75.00%	16,745,961	-83.72%	2	1.17%	29	-78.52%	20	-70.59%
Sep 30, 2025	101	-58.09%	20,268,240	-79.02%	2	1.61%	47	-63.85%	28	-59.42%
Jun 30, 2025	248	8.30%	97,673,633	-0.07%	13	7.50%	133	17.70%	70	-4.11%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
State Street® SPDR® S&P® Biotech ETF	7.32M	0.92%	16.81K
Vanguard Total Stock Mkt Idx Inv	3.71M	0.48%	-23.84K
Vanguard MStar Total Stk Mkt Idx Invest	3.73M	0.47%	17.69K
Vanguard Morn Total Stk Mkt Idx Investor	3.71M	0.46%	-23.84K
Vanguard US Total Market Shares ETF	3.43M	0.46%	-167.64K
Fidelity Growth Compy Commingled Pl S	3.53M	0.44%	-
Vanguard Small Cap Index	2.68M	0.34%	5.05K
Fidelity Growth Company Fund	2.65M	0.33%	-3.27K
SPDR® S&P Biotech ETF	2.43M	0.33%	5.41K
T. Rowe Price Health Sciences	2.53M	0.33%	-979.27K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 12, 2026	Zanganeh Mahkam	Co-Chief Executive Officer	Buy	$49.99M
Jun 12, 2026	DUGGAN ROBERT W	Co-Chief Executive Officer	Buy	$49.99M
Jun 04, 2026	DUGGAN ROBERT W	Co-Chief Executive Officer	Buy	$1.46M
Jun 04, 2026	Zanganeh Mahkam	Co-Chief Executive Officer	Buy	$1.46M
Jun 04, 2026	Soni Manmeet Singh	COO and CFO	Buy	$360.75K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	6	-
2026 Q1	-	-
2025 Q4	3	-
2025 Q3	4	-
2025 Q2	-	-

SMMT Ownership FAQ

Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 17.64%, followed by 80.89% insiders and 1.47% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 379.01%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (32.79M shares, 4.23%), Vanguard group (11.18M shares, 1.50%), and Fmr (10.04M shares, 1.30%). Together, they hold 7.03% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Apeiron capital is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.00% of its assets in 961.87K Summit Therapeutics shares, valued at 14.01M$.

Who is the top mutual fund holder of Summit Therapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Summit Therapeutics shares, with 0.92% of its total shares outstanding invested in 7.32M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools